Form 4 for INCY Incyte
Accepted 2025-07-17 00:00:00 ET · period of report 2025-07-15 · accession 0000879169-25-000089 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-07-17 | 2025-07-15 | INCY | Trotta Matteo | EVP, GM, Dermatology US | A - Grant | $0.00 | +5,261 | 15.0K | +54% | $0 |
| D | 2025-07-17 | 2025-07-15 | INCY | Trotta Matteo | EVP, GM, Dermatology US | F - Tax | $68.25 | -182 | 9,755 | -2% | -$12.4K |
| DM | 2025-07-17 | 2025-07-15 | INCY | Trotta Matteo | EVP, GM, Dermatology US | A - Grant | $0.00 | +25.0K | 11.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-15 | A | A | 5,261 | $0.00 | 15,016 | D | — | — | (F2) Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. (F3) Including the July 15, 2025 grant, this includes an aggregate of 13,117 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| 2 | Common | Common Stock | 2025-07-15 | F | D | 182 | $68.25 | 9,755 | D | — | — | (F1) Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. |
| 3 | Derivative | Performance Shares | 2025-07-15 | A | A | 13,154 | $0.00 | 13,154 | D | — · — to 2028-07-15 | 13,154 Common Stock | (F4) Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| 4 | Derivative | Employee Stock Option (right to buy) | 2025-07-15 | A | A | 11,841 | $0.00 | 11,841 | D | $68.25 · — to 2035-07-14 | 11,841 Common Stock | (F5) The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. |